Collaborators of Simmunext at Radboud University Medical Center publish new findings in Advanced Healthcare Materials underscoring the importance of T-cell phenotype and durability.
Cyclomics announced the successful closing of a new investment round led by Myosotis Investments and supported by the Oncode Bridge Fund, enabling team growth and the next phase of commercial expansion.
Laigo Bio closes Series A round to advance next-generation oncology therapeutics, supported by Oncode Oncology Bridge Fund I and leading life sciences investors.